8-K: Zymeworks Files Prospectus Supplements for Potential Share Issuance

Zymeworks Inc. has filed prospectus supplements related to the potential issuance of common stock, including shares issuable upon exchange of exchangeable shares and shares offered through an at-the-market (ATM) program.

Summary

• Zymeworks Inc. filed two prospectus supplements on May 3, 2024, related to its existing shelf registration statement.
• One supplement pertains to the potential issuance of up to 570,637 shares of common stock, which are issuable upon the exchange of exchangeable shares held by certain shareholders from a previous redomicile transaction.
• The other supplement relates to the potential offer and sale of up to $150 million worth of common stock through an at-the-market (ATM) offering program with Cantor Fitzgerald & Co. as the sales agent.
• These filings do not constitute an offer to sell or a solicitation to buy securities, and any sales will be subject to applicable securities laws.

Sentiment

Score: 5

Explanation: The document is neutral, detailing routine financial activities. While the potential for dilution is a concern, the company is taking steps to secure funding, which is a normal part of biotech operations.

Positives

• The company has the flexibility to raise capital through the ATM offering program.
• The legal opinions provided by Wilson Sonsini Goodrich & Rosati confirm the legality of the share issuances.

Negatives

• The potential issuance of new shares could dilute existing shareholders' ownership.
• The ATM offering indicates a need for additional capital, which may suggest the company is not generating sufficient cash flow from operations.

Risks

• The market may react negatively to the potential dilution of shares.
• The company's ability to successfully sell shares through the ATM program is subject to market conditions.
• There is no guarantee that the company will be able to raise the full $150 million through the ATM offering.

Future Outlook

The company intends to issue shares of common stock from time to time, as needed, through the exchange of exchangeable shares and the ATM offering program.

Management Comments

• Kenneth Galbraith, Chair, President, Chief Executive Officer and interim Chief Financial Officer, signed the report on behalf of Zymeworks Inc.

Industry Context

The use of ATM offerings is a common method for biotech companies to raise capital, especially when they are in the development stage and not yet generating significant revenue. This allows them to access funds without a large, dilutive secondary offering.

Comparison to Industry Standards

• Many biotech companies, such as Xencor and MacroGenics, utilize ATM offerings to raise capital as needed.
• The size of the ATM offering, $150 million, is within the typical range for companies of Zymeworks' size and stage.
• The use of a shelf registration statement and prospectus supplements is a standard practice for these types of offerings.

Stakeholder Impact

• Shareholders may experience dilution if the company issues a significant number of new shares.
• The company's ability to fund its operations and research programs may be improved by the capital raised.

Next Steps

• Zymeworks will continue to monitor market conditions and may issue shares through the ATM program as needed.
• The company will proceed with the exchange of exchangeable shares for common stock as per the terms of the agreements.

Key Dates

Keywords

Zymeworks, common stock, prospectus supplement, ATM offering, share issuance, capital raise, Cantor Fitzgerald, exchangeable shares, redomicile, Wilson Sonsini